CLEO Optimises Biomarker Panel Ahead of FDA Submission
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Cleo Diagnostics Ltd has announced the completion of its biomarker panel optimization ahead of an FDA submission, expanding the panel from five to eight biomarkers to enhance performance and manufacturability. The optimized panel is designed for the Ella platform, facilitating scalable global deployment while maintaining high throughput. A binding manufacturing agreement is expected soon, which will support the production of test kits for FDA analytical validation activities. This milestone is crucial for transitioning Cleo's Pre-Surgical Ovarian Cancer Test from research to a commercial-ready kit.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from CLEO Diagnostics
- Appendix 4D and Half Yearly Accounts
- CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
- Quarterly activities and cashflow report
- CLEO Raises $5m to Support U.S. Market Launch
- Trading Halt
Later from CLEO Diagnostics
- Sample Collection Completion for Pivotal US Clinical Trial
- CLEO Commences Kit Manufacturing Ahead of FDA Submission
- CLEO Establishes U.S. Reimbursement Pathway
- CLEO Enters Analytical Validation Phase
- Appendix 4G and Corporate Governance Statement
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics